Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome

Cardiology Journal

Volumn 15, Issue 3, 2008, Pages 209-219

  Riera, Andrés Ricardo Pérez ^a,f   Uchida, Augusto Hiroshi ^b   Ferreira, Celso ^a   Filho, Celso Ferreira ^a   Schapachnik, Edgardo ^c   Dubner, Sergio ^d   Zhang, Li ^e   Moffa, Paulo Jorge ^b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^d Clinica y Maternidad Suizo Argentina   (Argentina)

^e UNIVERSITY OF UTAH   (United States)

^f NONE   (Brazil)

Author keywords

Antiarrhythmic drugs; Long QT syndrome; Sudden cardiac death

Indexed keywords

AMBASILIDE; AMIODARONE; AMITRIPTYLINE; ANILIDE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BEPRIDIL; BRETYLIUM; CALCIUM CHANNEL L TYPE; CHROMANOL; CIMETIDINE; CIPROFLOXACIN; CK 3579; DELAYED RECTIFIER POTASSIUM CHANNEL; DESIPRAMINE; DOFETILIDE; DRONEDARONE; ERSENTILIDE; IBUTILIDE; ISOPRENALINE; MAGNESIUM SULFATE; MEGESTROL; PLACEBO; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; SEMATILIDE; SOTALOL; TEDISAMIL; TRECITILIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANKLE EDEMA; ANTIARRHYTHMIC ACTIVITY; BRADYCARDIA; CALCIUM CURRENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSPNEA; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BLOCK; HEART DEPOLARIZATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE POTENTIAL; HEART PALPITATION; HUMAN; HYPOTENSION; INFECTION; LIVER DYSFUNCTION; LONG QT SYNDROME; LUNG TOXICITY; MORTALITY; NAUSEA; NEUTROPENIA; NONHUMAN; POTASSIUM CURRENT; QT PROLONGATION; RECURRENT DISEASE; REVIEW; SODIUM CURRENT; SYNCOPE; TACHYCARDIA; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; ACTION POTENTIAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT;

ACTION POTENTIALS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; LONG QT SYNDROME;

EID: 54049134890     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Gupta A, Lawrence AT, Krishnan K et al. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J, 2007; 153: 891-899.
2. Lehtonen A, Fodstad H, Laitinen-Forsblom P et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm, 2007; 4: 603-607.
3. Mumford JL, Wu K, Xia Y et al. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environ Health Perspect, 2007; 115: 690-694.
4. Vyas H, Johnson K, Houlihan R et al. Acquired long QT syndrome secondary to cesium chloride supplement. J Altern Complement Med, 2006; 12: 1011-1014.
5. Barnay C, Taieb J, Morice R et al. Acquired long QT syndrome: a dominant problem? Ann Cardiol Angeiol (Paris), 2006; 55: 321-327.
6. Thomas D, Karle CA, Kiehn J. Modulation of HERG potassium channel function by drug action. Ann Med, 2004; 36: 41-46.
7. Linz DK, Afkham F, Itter G, Rütten H, Wirth KJ. Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with I(Kr)- and I(to)/IKur-blockade in vivo atrial electrical remodeling and antiarrhythmic drugs. J Cardiovasc Electrophysiol, 2007; 18: 1313-1320.
8. Ravina T, Ravina P, Gutierrez J. Acquired long QT syndrome: Unequal regression of Amiodarone induced repolarization lengthening. Int J Cardiol, 2008; 124: 395-399.
9. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA, 2007; 298: 1312-1322.
10. Yamada Y, Shiga T, Matsuda N et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J, 2007; 71: 1610-1616.
11. Carrió ML, Fortià C, Javierre C et al. Is short-term amiodarone use post cardiac surgery a cause of acute respiratory failure? J Cardiovasc Surg (Torino), 2007; 48: 509-512.
12. Mouallem M, Antipov N, Mayan H et al. Hyperglobulinemia in amiodarone-induced pneumonitis. Cardiovasc Drugs Ther, 2007; 21: 63-67.
13. Klein I, Danzi S. Thyroid disease and the heart. Circulation, 2007; 116: 1725-1735.
14. Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation, 1996; 94: 2572-2579.
15. Roukoz H, Saliba W. Dofetilide: A new class III antiarrhythmic agent. Expert Rev Cardiovasc Ther, 2007; 5: 9-19.
16. McBride BF, Min B, Kluger J et al. An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Ann Noninvasive Electrocardiol, 2006; 11: 163-169.
17. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med, 1999; 341: 857-865.
18. Ward KJ, Gill JS. Dofetilide: first of a new generation of class III agents. Expert Opin Investig Drugs, 1997; 6: 1269-1281.
19. Pedersen HS, Elming H, Seibaek M et al.; DIAMOND Study Group. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol, 2007; 100: 876-880.
20. Mykytsey A, Bauman JL, Razminia M et al. Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. J Cardiovasc Pharmacol Ther, 2007; 12: 36-43.
21. Tafreshi MJ, Rowles J. A review of the investigational antiarrhythmic agent dronedarone. J Cardiovasc Pharmacol Ther, 2007; 12: 15-26.
22. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc), 2006; 42: 75-86.
23. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and ratecontrolling effects. J Cardiovasc Electrophysiol, 2006; 17: 17-20.
24. Stoykov I, van Beeren HC, Moorman AF et al. Effect of amiodarone and dronedarone administration in rats on thyroid hormone-dependent gene expression in different cardiac components. Eur J Endocrinol, 2007; 156: 695-702.
25. Tschuppert Y, Buclin T, Rothuizen LE. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol, 2007; 27: 64: 785-791.
26. Naccarelli GV, Wolbrette DL, Samii S et al. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther, 2007; 5: 707-714.
27. Wadhani N, Sarma JS, Singh BN et al. Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions. J Cardiovasc Pharmacol Ther, 2006; 11: 184-190.
28. Celestino D, Medei E, Moro S et al. Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study. J Cardiovasc Pharmacol Ther, 2007; 12: 248-257.
29. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother, 2007; 41: 599-605.
30. Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med, 2007; 357: 987-999.
31. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J, 2003; 24: 1481-1487.
32. Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev, 2005; 23: 217-230.
33. Agelaki MG, Pantos C, Korantzopoulos P et al. Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. Eur J Pharmacol, 2007; 564: 150-157.
34. VerNooy RA, Mangrum JM. Azimilide, a novel oral class III antiarrhythmic for both supraventricular and ventricular arrhythmias. Curr Drug Targets Cardiovasc Haematol Disord, 2005; 5: 75-84.
35. Kerr CR, Connolly SJ, Kowey P et al. ASTAR Investigators. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol, 2006; 98: 215-218.
36. Pritchett EL, Kowey P, Connolly S, Page RL, Kerr C, Wilkinson WE. A-COMET-I Investigators. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J, 2006; 151: 1043-1049.
37. Camm AJ, Pratt CM, Schwartz PJ et al. AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo controlled trial of azimilide using heart rate variability for risk stratification. Circulation, 2004; 109: 990-996.
38. Pratt CM, Singh SN, Al-Khalidi HR et al. ALIVE Investigators. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol, 2004; 43: 1211-1216.
39. Dorian P, Borggrefe M, Al-Khalidi HR et al. SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation, 2004; 110: 3646-3654.
40. Lombardi F, Borggrefe M, Ruzyllo W et al. A-COMET-II Investigators. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: The A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J, 2006; 27: 2224-2231.
41. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues. Am J Cardiol, 2003; 91: 39D-44D.
42. Pratt CM, Al-Khalidi HR, Brum JM et al. Azimilide Trials Investigators. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol, 2006; 48: 471-477.
43. Kaźmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol, 2007; 30: 1043-1046.
44. Kafkas NV, Patsilinakos SP, Mertzanos GA et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol, 2007; 118: 321-325.
45. Hoyer AW, Balaji S. The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol, 2007; 30: 1003-1008.
46. Burkart TA, Kron J, Miles WM et al. Successful termination of atrial flutter by ibutilide during pregnancy. Pacing Clin Electrophysiol, 2007; 30: 283-286.
47. Sideris S, Bonios M, Melexopoulou C et al. The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm. Cardiology, 2007; 107: 399-401.
48. Mountantonakis SE, Moutzouris DA, Tiu RV et al. Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter. Am J Emerg Med, 2006; 24: 407-412.
49. Eidher U, Freihoff F, Kaltenbrunner W et al. Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia. Pacing Clin Electrophysiol, 2006; 29: 358-362.
50. Mazzocca G, Corbucci G, Venturini E et al. Is pretreatment with ibutilide useful for atrial fibrillation cardioversion when combined with biphasic shock? J Cardiovasc Med (Hagerstown), 2006; 7: 124-128.
51. Viktorsdottir O, Henriksdottir A, Arnar DO. Ibutilide for treatment of atrial fibrillation in the emergency department. Emerg Med J, 2006; 23: 133-134.
52. Zhang N, Guo JH, Zhang HCh et al. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract, 2005; 59: 1395-1400.
53. Kijtawornrat A, Hamlin RL, Hamlin DM. Effects of ambasilide in isolated perfused guinea pig heart: use dependence. Cardiovasc Toxicol, 2005; 5: 53-62.
54. Lerche C, Bruhova I, Lerche H et al. Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter. Mol Pharmacol, 2007; 71: 1503-1511.
55. Jost N, Virág L, Bitay M et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation, 2005; 112: 1392-1399.
56. Pajouh M, Wilson LD, Poelzing S et al. IKs blockade reduces dispersion of repolarization in heart failure. Heart Rhythm, 2005; 2: 731-738.
57. Sager PT, Nademanee K, Antimisiaris M et al. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans. Circulation, 1993; 88: 1072-1082.
58. Wong W, Pavlou HN, Birgersdotter UM et al. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol, 1992; 69: 206-212.